What are Vertex Pharmaceuticals's profit margins?

Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.

Where do Vertex Pharmaceuticals's ratios come from?

Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Vertex Pharmaceuticals VRTX Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Gross margin	344.9%+0.2pp	344.7%+0.1pp	344.5%+0.2pp	344.4%-0.3pp	344.7%-0.8pp
Returns
Return on invested capital	103.9%+32.2pp	71.8%+24.9pp	46.9%+26.9pp	20%+28.5pp	-8.5%-35.8pp
Efficiency
Asset turnover	2×0.0×	2×0.0×	2×0.0×	2×0.0×	2×0.0×
Liquidity
Current ratio	10.8×+0.4×	10.4×+0.2×	10.2×-0.1×	10.3×0.0×	10.3×-0.9×
Leverage
Debt-to-equity	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×+0.1×
Net debt / EBITDA	-3×—	——	——	——	——
Per Share
Book value per share	$281.46+4.4%	$269.49+3.3%	$260.77+2.9%	$253.43+3.7%	$244.33-3.0%
Valuation
Market capitalization	$444.5B-2.4%	$455.56B+2.5%	$444.24B-4.2%	$463.87B-1.1%	$469.26B+3.7%
Price / sales	37.6×-1.9×	39.5×+0.2×	39.3×-2.7×	42×-1.6×	43.6×+0.6×
Price / book	24.6×-1.7×	26.2×-0.2×	26.4×-1.9×	28.3×-1.5×	29.7×+1.7×
EV / EBITDA	97.1×—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Vertex Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Vertex Pharmaceuticals's profit margins?: Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
Where do Vertex Pharmaceuticals's ratios come from?: Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.